A Vaccine (VSV-hIFNβ-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Recruiting

Phase 1

VSV-hIFNβ-NIS, Cyclophosphamide, Ipilimumab, Nivolumab, CemiplimabA Vaccine (VSV-hIFNβ-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Sponsor:

Mayo Clinic

Code:

NCT03017820

Conditions

B-Cell Non-Hodgkin Lymphoma

Histiocytic and Dendritic Cell Neoplasm

Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome

Recurrent Adult Acute Myeloid Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy

Biospecimen Collection

Bone Marrow Biopsy

Computed Tomography

Cyclophosphamide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-17. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2024-12-11.